Health care costs related to home spirometry in the eICE randomized trial

Acute pulmonary exacerbations (PEs) are key clinical events for CF patients and pose a significant threat to their long term lung function [1]. In 25% of PEs, lung function does not recover to baseline [2 –4]. PEs have also been connected to decreased quality of life even after controlling for lung function, nutritional status and demographic factors [5]. In addition, PE-associated healthcare costs are high, as patients experiencing acute PEs are likely to be hospitalized and receive intravenous (I V) antibiotics [6,7].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research